<DOC>
	<DOCNO>NCT00621777</DOCNO>
	<brief_summary>Varenicline ( Chantix ) smoke cessation treatment approve 2006 FDA treatment nicotine dependence may particularly beneficial smoker schizophrenia bipolar disorder . Early experience varenicline indicate effective smoke cessation schizophrenia addition , potential therapeutic cognitive dysfunction population . In addition , data need evaluate safety , tolerability effectiveness Varenicline people bipolar disorder . To assess possibility , evaluate safety efficacy 12 month varenicline schizophrenia bipolar disorder patient able quit smoke short term treatment . To , enroll 324 smoker schizophrenia bipolar disorder 6 mental health clinic Massachusetts , New Hampshire , Michigan Minnesota open , 12-week smoking cessation program include varenicline added weekly group cognitive behavioral therapy ( CBT ) . Those achieve least 2 week continuous abstinence last 2 week open intervention randomize relapse prevention phase : 40-week , double blind , placebo-controlled trial varenicline dose use quit smoking add taper CBT schedule . Participants discontinue study medication behavioral treatment enter 3-month follow phase .</brief_summary>
	<brief_title>A Study Varenicline Prevention Relapse Smoking Patients With Schizophrenia Bipolar Disorder</brief_title>
	<detailed_description>Participants moderate heavy smoker , age 18-70 , smoke average ≥10 cigarettes/day past year quit past year period &gt; 1 month . During 12-week open phase smoke cessation program , eligible subject give active varenicline addition 13-session weekly cognitive behavioral therapy program smoking cessation . Dr. Evins ( Principal Investigator ) co-investigator meet subject individually Baseline Smoking Cessation Program assess medical eligibility varenicline . A chart review also conduct research physician psychiatrist . Dr. Evins another prescribe co-investigator write prescription varenicline medically eligible subject . Subjects receive study medication end weekly group meeting . Any subject experience serious side effect medication meet Dr. Evins another medical co-investigator individually . Subjects set quit date fourth fifth CBT session week . Self-reports exhale carbon monoxide ( CO ) level use assess smoke status . Those subject abstinent ≥2 week end 12th session group eligible 40-week relapse prevention program . After enrol Relapse Prevention Program , subject randomize receive varenicline placebo addition CBT relapse prevention . At Week 12 ( week end Smoking Cessation Program ) , Dr. Evins another prescribe co-investigator write prescription subject eligible randomized Relapse Prevention phase ( i.e . successful quitter ) ; prescription send Massachusetts General Hospital Research Pharmacy , fill accord randomization code research pharmacist create . When subject come CBT orientation group session Relapse Prevention Program ( Week 13 ) , receive 1-month supply varenicline placebo pill . During randomized Relapse Prevention phase , medication compliance assess every group meet pill-count . Subjects ask medication compliance side effect group CBT group leader staff . Any subject experience serious side effect medication meet Dr. Evins another medical co-investigator individually . In addition , Dr. Evins medical co-investigator review adverse event form subject every week . Again , self-report CO level use monitor smoke status . Before open randomize relapse prevention phase , subject periodically assess cognitive performance , clinical characteristic , adverse event order evaluate effect withdrawal , predictor cessation relapse , medication side effect . Following completion 40-week relapse prevention phase , 3 follow-up assessment perform 3-month period evaluate smoking status , cognitive functioning , clinical effect .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Varenicline</mesh_term>
	<criteria>Women men age 1870 DSMIV diagnosis schizophrenia , schizoaffective disorder bipolar disorder diagnostic interview chart review Smoke least 10 cigarette per day Clinically stable , stable dose antipsychotic ( schizophrenia ) mood stabilizer ( bipolar ) medication least 1 month No current active suicidal ideation Expired air carbon monoxide ( CO ) concentration &gt; 9 ppm Willing take study medication set quit date within 23 week begin treatment willing participate relapse prevention followup portion study Women childbearing potential must negative urine pregnancy test baseline agree use approve form contraception study . DSMIV diagnosis dementia , neurodegenerative disease , organic mental disorder Substance use disorder nicotine caffeine last 6 month Major depressive disorder within last 6 month Serious unstable medical illness include , cardiovascular , hepatic , renal , respiratory , endocrine , neurological , hematological disease hospitalization treatment illness likely within next 2 month Lifethreatening arrhythmia cerebrovascular event within 6 month , cardiovascular event within 2 month uncontrolled hypertension History multiple head injury neurological sequela , single severe head injury last neurological sequela , current CNS tumor Liver function test elevate twice normal Renal insufficiency estimate creatinine clearance &lt; 40 ml/min Plan continue use tobacco product othe cigarette ( e.g. , cigar , pipe ) Use investigational medication device past 30 day Current suicidal homicidal ideation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>bipolar disorder</keyword>
	<keyword>varenicline</keyword>
	<keyword>smoke cessation</keyword>
	<keyword>relapse prevention</keyword>
	<keyword>cognitive behavioral therapy</keyword>
</DOC>